Notes

Quick clinical recaps, summarised from the Malaysian CPGs.

• Nota Medik

  Dyslipidaemia: CV Risk, LDL-C Targets, Statins, Escalation & Doses

  Recap of the Malaysian CPG Management of Dyslipidaemia 2023: screening, CV risk categories and LDL-C targets, when to start drugs, statin intensities, add-on therapy, monitoring, statin intolerance and de-escalation, high triglycerides, special groups, and usual doses of lipid-lowering drugs.

• Nota Medik

  Hypertension: Classification, BP Targets, Drug Choice, Escalation & Doses

  Recap of the Malaysian CPG Management of Hypertension: BP classification and risk stratification, when to start drugs, BP targets by patient group, first-line and combination choices, escalation, step-down, hypertension in diabetes, and the usual starting and maximum doses of antihypertensives.

• Nota Medik

  Type 2 Diabetes: HbA1c Targets, Drug Choice, Escalation, De-escalation & Doses

  Recap of the Malaysian CPG Management of T2DM: targets for control, individualised HbA1c, starting treatment by HbA1c, choosing drugs by patient profile, escalation every 3-6 months, insulin initiation and titration, de-escalation, and usual doses of glucose-lowering drugs with renal adjustment.